Cindy Vavro

2.7k total citations · 1 hit paper
26 papers, 1.5k citations indexed

About

Cindy Vavro is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Cindy Vavro has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Infectious Diseases, 21 papers in Virology and 5 papers in Emergency Medicine. Recurrent topics in Cindy Vavro's work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (21 papers) and HIV/AIDS Research and Interventions (13 papers). Cindy Vavro is often cited by papers focused on HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (21 papers) and HIV/AIDS Research and Interventions (13 papers). Cindy Vavro collaborates with scholars based in United States, United Kingdom and France. Cindy Vavro's co-authors include M H St Clair, Paul Kellam, Brendan Larder, David M. King, Sharon D. Kemp, Gareth Tudor‐Williams, J L Martin, Mark S. Shaefer, Paul Wannamaker and Denise Sutherland‐Phillips and has published in prestigious journals such as Science, The Lancet and Journal of Clinical Microbiology.

In The Last Decade

Cindy Vavro

23 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase

1991 587 citations M H St Clair, J L Martin et al. Science profile →

Peers

Countries citing papers authored by Cindy Vavro

Since Specialization

Citations

This map shows the geographic impact of Cindy Vavro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cindy Vavro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cindy Vavro more than expected).

Fields of papers citing papers by Cindy Vavro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cindy Vavro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cindy Vavro. The network helps show where Cindy Vavro may publish in the future.

Co-authorship network of co-authors of Cindy Vavro

This figure shows the co-authorship network connecting the top 25 collaborators of Cindy Vavro. A scholar is included among the top collaborators of Cindy Vavro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cindy Vavro. Cindy Vavro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of the Two-Drug Regimen Dolutegravir–Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b Trial 2025 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Thanyawee Puthanakit, Linda Aurpibul, (unknown), (unknown), (unknown), (unknown), S.Y. Amy Cheung, (unknown), Ann M. Buchanan, Cindy Vavro, Michael J. McKenna, Sherene Min, Lionel Tan	0
2	Integrated Population Exposure–Response of Dolutegravir in HIV‐1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics 2024 ·Clinical Pharmacology & Therapeutics ·Hardik Chandasana, M. Bush, Cindy Vavro, Jenny Huang, Mounir Ait‐Khaled, Brian Wynne, Sherene Min, Rashmi Mehta	0
3	Sensitive HIV-1 DNA Pol Next-Generation Sequencing for the Characterisation of Archived Antiretroviral Drug Resistance 2023 ·Viruses ·(unknown), Matthew Byott, Moira Spyer, Paul R. Grant, Kathleen Gärtner, (unknown), James O. Burton, Alasdair Bamford, Laura Waters, Carlo Giaquinto, Anna Turkova, Cindy Vavro, Eleni Nastouli	1
4	Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by Race Subgroups 2016 ·Open Forum Infectious Diseases ·Debbie Hagins, Craig Dietz, Mamta K. Jain, (unknown), Indira Brar, Choy Man, (unknown), (unknown), Brian Wynne, Cindy Vavro, Michael Aboud, Kimberly Y. Smith	10
5	Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study 2014 ·Antiviral Therapy ·Bisher Akil, Gary Blick, Debbie Hagins, Moti Ramgopal, Gary Richmond, Rafik Samuel, Naomi Givens, Cindy Vavro, Ivy Song, Brian Wynne, Mounir Ait‐Khaled, (unknown)	61
6	Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Frank A. Post, Graeme Moyle, (unknown), Peré Domingo, Daniel Podzamczer, Martin Fisher, Anthony G.W. Norden, Matthias Cavassini, Armin Rieger, Marie-Aude Khuong-Josses, Teresa Branco, Helen Pearce, Naomi Givens, Cindy Vavro, Michael L. Lim	168
7	Similar Virologic and Immunologic Efficacy With Fosamprenavir Boosted With 100 mg or 200 mg of Ritonavir in HIV-Infected Patients: Results of the LESS Trial 2010 ·HIV Clinical Trials ·Calvin Cohen, Edwin DeJesus, Anthony LaMarca, Benjamin Young, Linda Yau, Lisa Patel, Cindy Vavro, Mary Beth Wire, Paul Wannamaker, Mark S. Shaefer	3
8	Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment 2009 ·AIDS ·Kimberly Y. Smith, Parul Patel, Derek M. Fine, Nicholaos Bellos, Louis Sloan, Philip Lackey, Princy Kumar, Denise Sutherland‐Phillips, Cindy Vavro, Linda Yau, Paul Wannamaker, Mark S. Shaefer	167
9	Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks 2009 ·HIV Clinical Trials ·Federico Pulido, Vicente Estrada, (unknown), (unknown), Knud Schewe, Andreas Plettenberg, Dan Duiculescu, (unknown), Cindy Vavro, Michael L. Lim, (unknown)	25
10	Evaluation of a Real-Time Nucleic Acid Sequence-Based Amplification Assay Using Molecular Beacons for Detection of Human Immunodeficiency Virus Type 1 2006 ·Journal of Clinical Microbiology ·Daniel McClernon, Cindy Vavro, Marty St. Clair	15
11	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial 2006 ·The Lancet ·Joseph J. Eron, Patrick Yéni, Joseph Gathe, Vicente Estrada, Edwin DeJesus, Schlomo Staszewski, Philip Lackey, Christine Katlama, Benjamin Young, Linda Yau, Denise Sutherland‐Phillips, Paul Wannamaker, Cindy Vavro, Lisa Patel, (unknown), Mark S. Shaefer	258
12	Fosamprenavir Clinical Study Meta-Analysis in ART-Naïve Subjects: Rare Occurrence of Virologic Failure and Selection of Protease-Associated Mutations 2006 ·HIV Clinical Trials ·Lisa Ross, Cindy Vavro, (unknown), Qiming Liao	9
13	Abacavir and Lamivudine Fixed-Dose Combination Tablet Once Daily Compared With Abacavir and Lamivudine Twice Daily in HIV-Infected Patients Over 48 Weeks (ESS30008, SEAL) 2005 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Néstor Sosa, Christina Hill‐Zabala, Edwin DeJesus, (unknown), Allison Florance, Maria Watson, Cindy Vavro, Mark S. Shaefer	32
14	Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors 2004 ·The Pediatric Infectious Disease Journal ·Janet A. Englund, Claire Raskino, Cindy Vavro, Paul Palumbo, Lisa Ross, Ross E. McKinney, (unknown), Robert C. Colgrove, Carol J. Baker	6
15	Substitution of a commercially available, RNA extraction procedure in an HIV-1 genotyping system improves sensitivity and allows reduced sample volume 2001 ·Journal of Virological Methods ·Lisa Ross, Cindy Vavro, (unknown), Daniel McClernon, Marty St. Clair	4
16	Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study 2001 ·The Pediatric Infectious Disease Journal ·(unknown), Megan Valentine, Janet Ottinger, Ruth Baydo, (unknown), Cindy Vavro, Kent J. Weinhold, Marty St. Clair, Ross E. McKinney	19
17	Treatment Intensification with Abacavir in HIV-Infected Patients with at Least 12 Weeks Previous Lamivudine/Zidovudine Treatment 2001 ·Antiviral Therapy ·Willy Rozenbaum, Christine Katlama, Patrice Massip, Michelle Bentata, David Zucman, Jean‐François Delfraissy, Christian Trépo, (unknown), E. Randall Lanier, Cindy Vavro, (unknown)	6
18	Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients 1998 ·The Pediatric Infectious Disease Journal ·Megan Valentine, (unknown), Cindy Vavro, Catherine M. Wilfert, Daniel McClernon, Marty St. Clair, Samuel L. Katz, (unknown)	26
19	Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus 1997 ·The Pediatric Infectious Disease Journal ·(unknown), Cindy Vavro, Megan Valentine, Kevin N. Pennington, E. Randall Lanier, Samuel L. Katz, John H. DiLiberti, (unknown), Catherine M. Wilfert, M H St Clair	41
20	Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase breakdown → 1991 ·Science ·M H St Clair, J L Martin, Gareth Tudor‐Williams, (unknown), Cindy Vavro, David M. King, Paul Kellam, Sharon D. Kemp, Brendan Larder	587

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact